Practice
Featured experience
GSK collaboration with Flagship Pioneering
We are advising GSK on the transaction
Azul $800 million secured notes offering
The senior secured notes are due 2028
Kenvue $4.37 billion IPO
The carve-out of the former Johnson & Johnson consumer health business is the largest U.S. IPO since November 2021
NBCUniversal partnership with MultiChoice to relaunch Showmax using Peacock
We are advising NBCUniversal on the transaction to relaunch MultiChoice’s Showmax service using the Peacock platform
IDEAYA Biosciences, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 5,750,000 shares of common stock of…
Davis Polk Advises Freeport-McMoRan on the Sale of a Portion of Its Cobalt Business to Umicore
Davis Polk is advising Freeport-McMoRan Inc. (“FCX”) on its agreement to sell its cobalt refinery in Kokkola, Finland and…
VF spinoff of Kontoor Brands
Davis Polk advised V.F. Corporation in connection with the spinoff of its wholly owned subsidiary, Kontoor Brands, Inc.,…
Natura acquisition of Avon
Davis Polk is advising Natura Cosméticos S.A. on its all-share acquisition of Avon Products, Inc. The transaction, which is…
Davis Polk Advises Comcast on Its Acquisition of Deep Blue Communications
Davis Polk advised Comcast Corporation in connection with its acquisition of Deep Blue Communications, LLC. Financial terms…
Fastly, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with a $207 million initial public offering…
Applied Therapeutics, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with a $40 million initial public offering…
Comcast agreement with Disney on Hulu’s future governance and ownership
Davis Polk is advising Comcast Corporation on its “put/call” agreement with The Walt Disney Company regarding NBCUniversal’s…
Uber Technologies $8.1 billion IPO
Davis Polk advised the underwriters in connection with the $8.1 billion initial public offering of 180,000,000 shares of…
NGM Biopharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 7,521,394 shares of common stock of NGM…